ISR Articles

  1. Small Molecule Drug Substance Outsourcing Drivers 10/4/2022

    ISR asked 57 respondents who outsource small molecule API which reason fits best with their company’s capacity for, and experience with, manufacturing small molecule drug substance. Read how the data shows the most common reason for outsourcing API manufacturing is a lack of capacity despite possessing in-house experience (42%).

     
  2. Biologic Drug Substance Outsourcing Drivers 10/4/2022

    ISR data from Q2 2022 shows the most common reason for outsourcing bioprocessing is a lack of capacity despite possessing in-house experience (41%).

  3. Understanding The Art And Science Of CRO Selection 9/19/2022

    This e-book examines the rationale behind how CROs are selected, why they are retained, and why sponsors opt for one provider or outsourcing model versus another.

  4. Outsourced Bioprocessing By Respondent Location 9/13/2022

    Europeans report outsourcing slightly more bioprocessing to China, while American respondents send more work to Japan and other Asia-Pacific manufacturing facilities (excluding China and India).

  5. Industry Trends: Clinical Logistics Outsourcing 8/29/2022

    Understanding industry trends, market dynamics, and the selection criteria decision-makers apply when choosing a clinical logistics service provider informs and contextualizes outsourcing decisions.

  6. The Right Choice: Using Consultants For CDMO Selection 7/12/2022

    In Q2 2022, ISR asked 99 outsourcers whether the company they work for uses consultants to help guide their CDMO selection process. Read the results from ISR’s CDMO Outsourcing Models (3rd Edition) to gain insight into the use of consultants during CDMO selection.

  7. Biologics Outsourcing Differences By Company Size 6/14/2022

    ISR split the data from its most recent Biologic API CDMO Benchmarking report by large and non-large respondents to highlight the differences in outsourcing preferences and practices.

  8. Drug Innovators' Outlook On Innovative Treatments 6/14/2022

    134 outsourcers of biologic drug substance provided insight into their pipelines are impactingoutsourcing practices. Two-thirds (63%) said a focus on new, innovative treatments will impact outsourcing decisions.

  9. Unraveling Hybrid Clinical Trials: Challenges And Opportunities 6/10/2022

    Hybrid trials have undergone rapid evolution in the past few years. Examine this evolution, the reasons for confidence and concern, and how they may impact pharmaceutical development in the future.

  10. Outsourcing Highly Potent API – It's What You Know And Who You Know 6/2/2022

    Discover challenges for drug makers who may want to produce higher potency APIs but have built their manufacturing systems around broad-spectrum medications that don’t require high-containment facilities.